CAF-DCF is a BENELUX company specialized in the commercialization of plasma derived medicines. We have long term expertise in life-saving products for rare and life-threatening diseases in three therapeutic domains : immunology, intensive care and hemostasis. Our driving values are : Ethical commitment Dedication to BENELUX healthcare services Safety of our products and of patients using them Trust The use of blood plasma drawn from volunteer donors and the preparation of products intended to save patients are the cornerstone of our "human-to-human approach". CAF-DCF is controlled by the French biopharmaceutical group LFB. The company has historically been founded by the Belgian Red Cross and has a 40 years history of ethical product development , production and commercialization in the field of plasma derived medicines.
| Website | http://www.caf-dcf.be |
| Revenue | $25.1 million |
| Employees | 36 (12 on RocketReach) |
| Phone | +32 2 264 64 41 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+9 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing |
| Keywords | Rare Disease Treatment, Immunology Therapeutics, Biopharmaceutical Products, Pharmaceutical Commercialization, Specialty Pharmaceuticals, Life Saving Drugs, Plasma Fractionation, Biologics, Therapeutic Proteins, Healthcare, Medical Products, Pharmaceutical Sales, Drug Distribution, Medicine Sales, Global Healthcare |
| Competitors | Siemens, Boeing, Thales, Alstom, BOMBARDIER, Hitachi Rail, Knorr-Bremse AG, Stadler, Ferrostaal GmbH, CAF Argelia +36 more (view full list) |
Looking for a particular CAF-DCF employee's phone or email?
The CAF-DCF annual revenue was $25.1 million in 2026.
Romuald Gaudefroy is the Managing Director of CAF-DCF.
12 people are employed at CAF-DCF.